Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties

by Montgomery W, Treuer T, Karagianis J, Ascher-Svanum H, Harrison G
Published 2012-02-01

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan

by Ye W, Ascher-Svanum H, Flynn JA, Tanji Y, Takahashi M
Published 2012-01-01

Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan

by Ye W, Ascher-Svanum H, Tanji Y, Flynn JA, Takahashi M
Published 2011-12-01

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, explorator...

by Ascher-Svanum H, Montgomery WS, McDonnell DP, Coleman KA, Feldman PD
Published 2012-05-01

The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy

by Montgomery W, Liu L, Stensl, MD, Xue HB, Treuer T, Ascher-Svanum H
Published 2013-08-01

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis

by Takahashi M, Flynn JA, Tanji Y, Ascher-Svanum H, Ye W, Conley RR
Published 2012-06-01

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection

by Ascher-Svanum H, Novick D, Haro JM, Bertsch J, McDonnell D, Detke H
Published 2014-06-01

Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy

by Peng X, Ascher-Svanum H, Faries DE, Stauffer VL, Kollack-Walker S, Kinon BJ, Kane JM
Published 2011-04-01

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia

by Ascher-Svanum H, Brnabic AJM, Lawson AH, Kinon BJ, Stauffer VL, Feldman PD, Kelin K
Published 2012-03-01

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

by Chen J, Ascher-Svanum H, Nyhuis AW, Case MG, Phillips GA, Schuh KJ, Hoffmann VP
Published 2011-11-01

Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia

by Chen L, Ascher-Svanum H, Lawson A, Stauffer VL, Nyhuis A, Haynes V, Schuh K, Kinon BJ
Published 2013-06-01

Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?

by Montgomery W, Treuer T, Ye W, Xue HB, Wu SH, Liu L, Kadziola Z, Stensl, MD, Ascher-Svanum H
Published 2014-07-01

Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation

by Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, Awad AG, Keefe RS, Naber D
Published 2012-07-01